Sath Shukla, Chief Financial Officer at Spero Therapeutics, Inc. (SPRO), sold 9,504 shares at $1.83 ($17K) on 2023-02-02, disclosed to the SEC on 2023-02-03.
Scheduled sale ($17k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-08-06 | $43K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $173K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $8K | — | Filing → |